Eplerenone: Research, Dosing, and Where to Buy in 2026
A research-first profile for Eplerenone (Eplerenone), aggregating mechanism notes, transcript dosing mentions, vendor recommendations, and PubMed-indexed literature without presenting medical guidance.
Eplerenone is a research compound profiled here from named-expert transcripts and peer-reviewed literature, without medical guidance. As of July 2026, The Peptide Wiki aggregates 8 PubMed-cited papers, and 3 attributed expert mentions for Eplerenone, each linked to its source.
- Also indexed as Eplerenone.
- 0 aggregated dosing-protocol mentions from source transcripts.
- 8 PubMed-indexed citations listed in the research table below.
- 0 vendor recommendations captured from named experts.
What is Eplerenone?
Research compound aggregated from creator and literature mentions. No direct disease-treatment claims are made on this page.
Experts on background and overview · 2 cited mentions
"Have you ever looked into eplerenone and hydrochlorothiazide for blood works amazing for me... Potassium-sparing diuretic selective mineralocorticoid receptor agonist used to treat high blood pressure... Doesn't seem like a good idea to me."
"Eplerenone's a mineralocorticoid receptor agonist raises potassium [discussed as bloating-reduction option alongside HCTZ; Steve plans to test DHT instead due to similar mineralocorticoid interaction]."
Eplerenone Dosing Protocols
The entries below are transcript-derived dosing mentions. They are preserved for research context and are not medical advice.
No transcript-derived dosing mentions in current source set.
Where to Buy Eplerenone in 2026
No tracked vendor recommendations for Eplerenone yet. See our vendor directory.
Side Effects and Safety
Anecdotal reports and study-level observations vary by route, dose, and individual. This page does not provide medical advice. Consult a qualified clinician before any research use.
What Experts Say
1 expert across our source library discuss Eplerenone. Each entry is that expert’s most context-rich mention: click to watch it at the exact timestamp in the original video. Quotes are also emitted as Schema.org Quotation JSON-LD for AI assistants.
-
“Have you ever looked into eplerenone and hydrochlorothiazide for blood works amazing for me... Potassium-sparing diuretic selective mineralocorticoid receptor agonist used to treat high blood...”
See 1 more expert mention →
-
“Eplerenone's a mineralocorticoid receptor agonist raises potassium [discussed as bloating-reduction option alongside HCTZ; Steve plans to test DHT instead due to similar mineralocorticoid interaction].”
User Reviews
User reviews aggregator coming Q3 2026 (Reddit + YouTube comments + Discord research notes). Until then, see the expert quote section above and PubMed citations below.
Research Efficacy Snapshot
Published efficacy percentages cited in PubMed trials and named-expert reports about Eplerenone. Each line links to the original source.
- "Dichotomous data were pooled as Hazard ratio (HR) or Risk ratio (RR) with a 95% confidence interval (CI)." · Elshahat A et al, 2024 PubMed
- "Eplerenone showed a lower risk of all-cause mortality (HR = 0.78, 95%CI [0.64 to 0.94], P = 0.009) and cardiovascular mortality (HR = 0.54, 95%CI [0.39, 0.74], P = 0.0001) compared to spironolactone." · Elshahat A et al, 2024 PubMed
- "Furthermore, eplerenone exhibited a reduced risk of treatment withdrawal (RR = 0.69, 95% CI [0.62, 0.78], P = 0.0001) and gynecomastia (RR = 0.07, 95% CI [0.02 to 0.31], P = 0.0001) than spironolactone." · Elshahat A et al, 2024 PubMed
- "Mean percentage change from baseline in UACR after 4 weeks of treatment with dapagliflozin, eplerenone, and dapagliflozin-eplerenone was -19.6% (95% confidence interval [CI], -34.3 to -1.5), -33.7% (95% CI, -46.1 to -18.5), and -53% (95% CI, -61.7 to -42.4; P<0.001 versus dapagliflozin; P=0.01 versus eplerenone)." · Provenzano M et al, 2022 PubMed
- "Hyperkalemia was more frequently reported with eplerenone (n=8; 17.4%) compared with dapagliflozin (n=0; 0%) or dapagliflozin-eplerenone (n=2; 4.3%; P between-groups=0.003)." · Provenzano M et al, 2022 PubMed
- "The proportions of patients achieving target sitting BP (<140/90 mm Hg) were 31.5%, 41.2%, and 27.5% with esaxerenone 2.5 and 5 mg/day and eplerenone 50 mg/day, respectively." · Ito S et al, 2020 PubMed
- "During a mean follow-up of 16 months, there were 478 deaths in the eplerenone group and 554 deaths in the placebo group (relative risk, 0.85; 95 percent confidence interval, 0.75 to 0.96; P=0.008)." · Pitt B et al, 2003 PubMed
- "Of these deaths, 407 in the eplerenone group and 483 in the placebo group were attributed to cardiovascular causes (relative risk, 0.83; 95 percent confidence interval, 0.72 to 0.94; P=0.005)." · Pitt B et al, 2003 PubMed
- "There was also a reduction in the rate of sudden death from cardiac causes (relative risk, 0.79; 95 percent confidence interval, 0.64 to 0.97; P=0.03)." · Pitt B et al, 2003 PubMed
- "The rate of serious hyperkalemia was 5.5 percent in the eplerenone group and 3.9 percent in the placebo group (P=0.002), whereas the rate of hypokalemia was 8.4 percent in the eplerenone group and 13.1 percent in the placebo group (P<0.001)." · Pitt B et al, 2003 PubMed
Research and Studies
8 PubMed-indexed papers reference Eplerenone. Top 8 shown.
Legal Status
Eplerenone is presented here as a research compound. FDA approval status, scheduling, WADA status, and state-specific telehealth rules may apply. Always verify current regulatory status. Last verified: 2026-07-09.
Frequently Asked Questions
Is Eplerenone FDA-approved?
Eplerenone is presented on this page as a research compound. FDA approval status, scheduling, and state-specific rules may apply and change. Verify current regulatory status before any decision.
How much research has been published on Eplerenone?
8 PubMed-indexed paper(s) reference Eplerenone in our current research feed. See the Research and Studies section above for citations.